BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.
BGI’s Targeted Drug Therapy Panel examines all exons and selected introns of 206 genes with direct therapeutic implications for 95 targeted therapies from a variety of sample input including fresh tissue, biopsy, FFPE, DNA and peripheral blood.
10 working days
Tissue - Fresh/Frozen tumor tissue, biopsy, FFPE, DNA + 5mL peripheral blood. ctDNA - Peripheral blood (10mL)
Target region capture, High-throughput sequencing
Ordering the BGI SENTIS™ Targeted Drug Therapy Panel is easy.
Physician orders test
Blood or saliva sample collected
Sample shipped to BGI and analyzed
Results sent to physician